4 results
8-K
EX-99.1
APLS
Apellis Pharmaceuticals, Inc.
27 Feb 24
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
7:30am
at the American Society of Hematology (ASH) Annual Meeting.
R&D Highlights
C3 glomerulopathy (C3G) and immune complex glomerulonephritis (IC-MPGN … were expensed as research and development (R&D) expense. This resulted in inventory being sold during the 2022 and 2023 periods, for which a portion
8-K
EX-99.1
APLS
Apellis Pharmaceuticals, Inc.
31 Jul 23
Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results
8:03am
-administration of EMPAVELI.
Rare Disease R&D Highlights
Amyotrophic lateral sclerosis (ALS): In May 2023, Apellis and Sobi discontinued development … inhibition + siRNA: In June 2023, Apellis enrolled its first patient in Phase 1 clinical trial with APL-3007.
Neurology R&D Highlights
APL-1030: Apellis
8-K
EX-99.1
APLS
Apellis Pharmaceuticals, Inc.
27 Oct 20
Sobi obtains global co-development and exclusive ex-U.S. commercialization rights for systemic pegcetacoplan, a targeted C3 therapy
7:17am
are excited to collaborate with Apellis, a leader in targeted C3 therapies. The collaboration will significantly strengthen and broaden our late-stage R&D portfolio
- Prev
- 1
- Next